Table 1.
Baseline characteristics of the Boston Kidney Biopsy Cohort
| Characteristics | n=676 |
|---|---|
| Age, yr | 52.2±16.5 |
| Women, % | 52.5 |
| Race, % | |
| White | 63.8 |
| Black | 20.6 |
| Other | 15.7 |
| eGFR, ml/min per 1.73 m2 | 57.5±36.0 |
| Serum creatinine, mg/dl | 1.41 [0.94–2.24] |
| Proteinuria, g/g creatinine | 1.74 [0.43–4.38] |
| No. of glomeruli on biopsy | 31 [20–43] |
| Reason for biopsy,a % | |
| Proteinuria | 59.2 |
| Hematuria | 27.4 |
| Nephrotic syndrome | 14.5 |
| Nephritic syndrome | 2.5 |
| Abnormal eGFR | 53.5 |
| Primary clinicopathologic diagnosis, % | |
| Proliferative GN | 30.2 |
| Nonproliferative glomerulopathies | 18.2 |
| Advanced glomerulosclerosis | 11.5 |
| Diabetic nephropathy | 11.1 |
| Vascular | 8.0 |
| Tubulointerstitial | 7.3 |
| Paraprotein | 7.3 |
| Other | 6.5 |
| Comorbid conditions, % | |
| Diabetes mellitus | 22.6 |
| Hypertension | 49.3 |
| SLE | 14.8 |
| Hepatitis C | 2.5 |
| Malignancy | 13.0 |
| Medications, % | |
| ACEi/ARB | 45.9 |
| Mineralocorticoid receptor antagonists | 1.9 |
| Calcium channel blockers | 23.4 |
| β-Blockers | 29.4 |
| Immunosuppression | 17.8 |
| Corticosteroids | 17.6 |
| Clinical site, % | |
| Site 1 | 57.8 |
| Site 2 | 32.0 |
| Site 3 | 10.2 |
Data presented as percentages, mean±SD, and median [interquartile range]. ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker.
a
Percentages do not add to 100, because there may have been multiple reasons for biopsy.